Perioperative Care of Children with Neuromuscular Disease


1. Motoneuron diseases

Spinal muscular atrophy (SMA), SMA with respiratory distress (SMARD)

Spinobulbar muscular atrophy (Kennedy disease)

Poliomyelitis

2. Peripheral neuropathies

Guillain–Barrè Syndrome (GBS)

Chronic inflammatory demyelinating polyneuropathy (CIDP)

Hereditary sensory and motor neuropathies (i.e., Charcot–Marie–Tooth disease)

Hereditary sensory and autonomic neuropathies (HSAN)

Critical illness polyneuropathy

3. Neuromuscular junction diseases

Myasthenia gravis (MG)

Congenital autoimmune myasthenia gravis

Congenital myasthenias

Botulism

4. Muscle diseases

Progressive muscular dystrophies

Dystrophinopathies: Duchenne (DMD) and Becker (BMD) type

Limb-girdle muscular dystrophies (LGMD)

Facioscapulohumeral muscular dystrophy (FSHD)

Oculopharyngeal muscular dystrophy (OPMD)

Myotonic dystrophy (DM): DM type 1 (DM1), DM type 2 (DM2 or PROMM disease)

Congenital muscular dystrophies

Ullrich CMD, Bethlem myopathy

Emery–Dreifuss dystrophy

Merosin-deficient CMD

Alpha-dystroglycanopathies (e.g., Fukuyama CMD)

Congenital myopathies

Central core disease/malignant hyperthermia

Nemaline/rod myopathies

Centronuclear/myotubular myopathy

Fiber-type disproportion myopathy

Myofibrillar myopathies

Metabolic myopathies

Mitochondrial encephalomyopathies

Glycogen storage disorders (i.e., GSD type II or Pompe disease, McArdle disease)

Lipid storage myopathies



An intensive, proactive, multidisciplinary approach should be instituted before, during, and after any surgical procedure requiring GA or sedation. Thus, surgery in this children population should be performed in a fully equipped hospital with extensive experience in NMD management.

This chapter will review the pathophysiology of life-threatening complications of anesthesia in NMDs and the assessment and management of these children before, during, and after anesthesia.



12.2 Life-Threatening Complications of Anesthesia in NMDS



12.2.1 Respiratory Failure


Respiratory involvement can vary significantly between different NMDs and within each type of disorder. Reduction of inspiratory muscle strength results initially in restrictive pulmonary impairment with a progressive decrease of forced vital capacity (FVC). Subsequently, ineffective alveolar ventilation may occur, leading to nocturnal hypercapnia and eventually to diurnal hypercapnia. In addition, weakness of expiratory muscles leads to inadequate clearance of airway secretions. Hypoventilation, coupled with an impaired cough, predisposes to atelectasis and respiratory failure. Furthermore, patients with NMDs often experience mild to moderate bulbar dysfunction, affecting their ability to swallow. Children with type 1 spinal muscular atrophy (SMA), myasthenia gravis (MG), and with other rapidly progressive NMDs may develop a more severe bulbar dysfunction with an increased likelihood of aspiration. Finally, respiratory status can be further impaired by sleep apneas, nutritional problems, gastroesophageal reflux, or progressive scoliosis. In patients with compromised respiratory function, anesthetic agents may further decrease respiratory muscle strength, exacerbating hypoventilation, airway secretion retention, aspiration, and obstructive and central apneas. These conditions may lead to nosocomial infections, prolonged intubation, tracheotomy, and eventually death.


12.2.2 Cardiovascular Failure


Several NMDs are associated with cardiac dysfunctions (cardiomyopathies and/or abnormality of the conduction system) as shown in Table 12.2. However, clinical manifestations of heart failure are often unrecognized until very late stage, owing to musculoskeletal limitations. All children with relevant cardiac dysfunctions have a limited ability to increase cardiac output in response to stress. Consequently, they are at high risk for perioperative cardiac side effects due to negative inotropic effect of volatile and i.v. anesthetic agents, positive pressure ventilation, hypoxemia, and acute anemia. Volatile anesthetics may also induce arrhythmia resulting from sensitization of the heart to catecholamines and from inhibitory effects on voltage-gated K+ channels. Finally, children with NMDs with respiratory involvement leading to nocturnal hypoxemia may be affected by right ventricular changes because of pulmonary hypertension.


Table 12.2
Cardiac dysfunction in children with neuromuscular disorders


































Disorder

Cardiac dysfunction

Guillain–Barrè syndrome, SMA type 1, a subgroup of hereditary neuropathies

Dysautonomia may enhance cardiovascular instability (i.e., bradycardia, blood pressure shifts)

Dystrophinopathies

Dilated cardiomyopathy (very common; broad spectrum of severity including severe cardiac failure); arrhythmias and conduction defects (<10 % of patients)

Limb-girdle muscular dystrophies (LGMD)

Arrhythmias and conduction defects (common); dilated cardiomyopathy (rare in LGMD type 2A, 2D)

Myotonic dystrophies

Arrhythmias and conduction defects (common); dilated cardiomyopathy (rare)

Congenital myopathies

Arrhythmias and conduction defects; dilated cardiomyopathy

Mitochondrial encephalomyopathies

Arrhythmias and conduction defects; dilated cardiomyopathy

Glycogen storage diseases type II

Cardiomyopathy (hypertrophic cardiomyopathy in the infantile form)

Lipid storage myopathies

Cardiomyopathy


12.2.3 Malignant Hyperthermia (MH)


It is a rare inherited drug-induced disorder of the skeletal muscle characterized by an increased muscle metabolism with excessive heat, carbon dioxide and lactate production, high oxygen consumption, contractures of the muscles, and myofiber breakdown. It is usually triggered when an MH-susceptible individual is exposed to a halogenated agent or succinylcholine and in rare cases to strenuous exercise and/or heat exposure.


12.2.3.1 Patients at Risk






  • Diagnosis of ryanodine receptor 1 (RYR1) mutations or central core disease (CDC)


  • Relatives of MH or CCD patients


  • Few muscle diseases:



    • Central core disease


    • Core-rod myopathy


    • King–Denborough syndrome


12.2.3.2 Prevention






  • Choice of anesthesia: “trigger-free” anesthetic and “clean” anesthesia machine for halogenated agents. The anesthesia machine must be prepared by using a disposable circuit, a fresh CO2 absorbent, disconnecting the vaporizers and flushing with O2 at a rate of 10 L min for at least 20 min before use. However, these recommendations are derived from older-style anesthetic machines, and modern anesthetic workstations may need longer cleaning times to wash out residual inhalational anesthetics in order to establish an acceptable concentration below 5 ppm.


  • Availability of sufficient quantities of dantrolene in order to treat MH: dantrolene (vials, 20 mg each).


  • Adequate intra- and postoperative monitoring: carefully monitoring for signs of rhabdomyolysis (i.e., serial plasma CK and myoglobin and urine myoglobin), capnometry, and measurement of body temperature.


12.2.3.3 Management of Acute Crisis






  • Discontinue inhalational agents and use non-triggering agents for the remainder of the procedure.


  • Hyperventilate with 100 % oxygen and intubate with endotracheal tube.


  • Give dantrolene: loading bolus of 2.5 mg/kg i.v., with subsequent bolus doses of 1 mg/kg i.v. until the signs of acute MH have abated; 1 mg/kg every 6 h should be continued for 48 h after the last observed sign of acute MH to prevent recrudescence.


  • Give sodium bicarbonate for acidosis.


  • Cool the patient (cold saline for infusion, ice to body surface); lavage body cavities (e.g., stomach, bladder, rectum). Maintain temperature <39 °C.


  • Treat hyperkalemia:



    • To antagonize the myocardial effects of hyperkalemia, give immediately calcium chloride i.v. (repeat the dose after 5 min if ECG changes persist).


    • To shift potassium back into muscle cells hyperventilate, give sodium bicarbonate and insulin with 10 % dextrose (monitor finger stick glucose closely).


  • Treat dysrhythmias: usually responds to treatment of acidosis and hyperkalemia; use standard ACLS protocols; calcium channel blockers are contraindicated in the presence of dantrolene.


12.2.4 Rhabdomyolysis


It is an uncommon but potentially fatal disorder triggered by succinylcholine or halogenated agents in susceptible patients, characterized by muscle necrosis with release of intracellular muscle constituents (i.e., myoglobin, potassium, and creatine kinase) into the circulation. It can be acute, resulting in hyperkalemic cardiac arrest, or subacute, presenting as dark urine, acute kidney failure, or cardiac arrest in the postanesthetic care unit.


12.2.4.1 Patients at Risk






  • Succinylcholine may cause rhabdomyolysis in almost all neuromuscular diseases but especially if muscles are denervated, progressively dystrophic, or metabolically altered.


  • Halogenated agents may cause rhabdomyolysis in patients with myopathies (especially dystrophinopathies and metabolic myopathies).


12.2.4.2 Prevention






  • “Trigger-free” anesthetic and “clean” anesthesia machine for halogenated agents (see malignant hyperthermia)


  • Adequate intra- and postoperative monitoring: carefully monitoring for signs of rhabdomyolysis up to 12 h postoperatively (i.e., serial plasma CK and myoglobin and urine myoglobin)


12.2.4.3 Management of Acute Crisis






  • Treat hyperkalemia (see malignant hyperthermia).


  • Prevent heme pigment-induced acute kidney injury:



    • Early and aggressive fluid resuscitation with isotonic saline to maintain the urine output greater than 1 mL/kg/h.


    • Loop diuretics may be given to patients who develop volume overload as a result of aggressive volume administration.


    • Alkalinization of urine: administration of an alkaline solution to maintain the urine pH above 6.5, providing the patient is not severely hypocalcemic and has an arterial pH less than 7.5 and a serum bicarbonate less than 30 meq/L.


  • Treat acute kidney injury: dialysis may be necessary for control of hyperkalemia and correction of acidosis or for the treatment of volume overload.


12.2.5 Hyperkalemic Cardiac Arrest Secondary to Denervation


It is a cardiac arrest due to hyperkalemia triggered by succinylcholine in the presence of striated muscle denervation hypersensitivity (upregulation of nicotinic acetylcholine receptors).


12.2.5.1 Pathologies at Risk






  • Motoneuron diseases


  • Peripheral neuropathies


12.2.5.2 Prevention


Avoid succinylcholine in children with motoneuron diseases or peripheral neuropathies.


12.2.5.3 Management of Acute Crisis






  • Use standard ACLS protocols.


  • Shift potassium back into muscle cells, give sodium bicarbonate and insulin with 10 % dextrose, and hyperventilate.


  • Continue cardiopulmonary resuscitation until serum potassium levels are lowered to a near normal level.


12.3 Preoperative Assessment and Management



12.3.1 Neurological Assessment


Detailed diagnosis is essential to assess the risk during surgery and anesthesia. Thus, preoperative assessment must include a neurological examination to confirm the diagnosis, when feasible, and to identify the level of progression of the disease in each patient. However, diagnostic process may be complex and some patients may lack a definite diagnosis, particularly those manifesting only with isolated elevated creatine kinase levels with or without minor signs. These children are particularly at risk of life-threatening complications related to anesthesia and should be treated as subjects at highest risk level.


12.3.2 Pulmonary Assessment


In all children with NMDs, preoperative pulmonary evaluation is strongly recommended to assess the risk of respiratory complications and the need for specific perioperative and postoperative management.

Assessment of respiratory function should include an accurate medical history and physical examination, a chest x-ray, an evaluation of sleep-disordered breathing, and the measurements of respiratory function and cough effectiveness. Evaluation of respiratory function and cough effectiveness includes measurement of FVC, peak cough flow (PCF), and diurnal pulse oximetry (SpO2). SpO2 less than 95 % in room air has been established as a clinically significant threshold of abnormality, requiring carbon dioxide (PCO2) level measurement. Preschool or older patients with developmental delay may not be able to perform evaluation tests of respiratory function and cough effectiveness. In these cases, the measurement of the crying vital capacity (i.e., FVC obtained from a tightly fitted mask over the nose and mouth with in-line spirometer) can approximate FVC.

It is crucial to optimize the patient’s respiratory status before surgery. When respiratory function measurements and sleep studies are abnormal, noninvasive ventilation (NIV) and manual or mechanically assisted cough techniques may be indicated. Therefore, planning and coordination with the hospital respiratory therapists is crucial. In particular, mechanical insufflator–exsufflator (MI-E) can increase coughing, promote deep lung inflation, and treat or prevent atelectasis. Consequently, patients with limited respiratory reserve should be trained in these techniques before surgery and assisted with these devices during sedation, regional anesthesia, and in the postoperative period. This strategy is also recommended for patients already using assisted cough techniques and long-term NIV.

Recently, preoperative training in the use of NIV has been recommended for patients with Duchenne muscular dystrophy (DMD) with preoperative FVC <50 % of predicted value and especially for patients at high risk of respiratory failure, defined by an FVC <30 % of predicted value. Moreover, for children over 12 years of age, if PCF is less than 270 L/min, training in assisted cough techniques is advocated before surgery. This strategy has the potential to be applied to adults and children with respiratory involvement resulting from diagnosis other than DMD.


12.3.3 Cardiac Assessment


Children with NMDs should undergo a careful assessment of cardiac function as well as optimization of therapy before anesthesia or sedation. In all children with NMDs, an electrocardiogram and echocardiogram should be performed before anesthesia or sedation, if not done in the previous 12 months. Moreover, signs or symptoms of arrhythmias should be promptly investigated with a Holter test. In addition, patients with a high degree of AV blocks may need a cardiac pacemaker before GA.

In all patients with severe cardiac dysfunctions, invasive arterial pressure should be monitored during GA and in the postoperative period.

In children with NMDs without primary myocardial dysfunction (e.g., SMA), preoperative cardiologic evaluation is suggested only if pulmonary hypertension is suspected.


12.3.4 Other Issues


Nutritional status should be optimized before surgery. In case of poor nutritional balance, wound healing can be delayed and the patient could be too weak to adequately clear secretions or maintain ventilation.

Patients with NMDs have an increased sensitivity to premedication drugs, which could induce apnea and hypoventilation.

Only gold members can continue reading. Log In or Register to continue

Sep 22, 2016 | Posted by in ANESTHESIA | Comments Off on Perioperative Care of Children with Neuromuscular Disease

Full access? Get Clinical Tree

Get Clinical Tree app for offline access